ArticlePharmacoEconomics2025
Cost Effectiveness of Tremelimumab Plus Durvalumab for Unresectable Hepatocellular Carcinoma in the USA.
Xiaomo Xiong et al.PubMed ↗Publisher ↗
No numbers read from the abstract.
5 papers cite it
this papercites it
ArticlePharmacoEconomics2025
Xiaomo Xiong et al.PubMed ↗Publisher ↗
No numbers read from the abstract.